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ttp://dx.doi.org/10.1016/j.ajpath.2014.06.002The mechanistic target of rapamycin (mTOR) is a central regulator of cellular responses to environ-
mental stress. mTOR (and its primary complex mTORC1) is, therefore, ideally positioned to regulate lung
inﬂammatory responses to an environmental insult, a function directly relevant to disease states such
as the acute respiratory distress syndrome. Our previous work in cigarette smokeeinduced emphysema
identiﬁed a novel protective role of pulmonary mTORC1 signaling. However, studies of the impact of
mTORC1 on the development of acute lung injury are conﬂicting. We hypothesized that Rtp801, an
endogenous inhibitor of mTORC1, which is predominantly expressed in alveolar type II epithelial cells,
is activated during endotoxin-induced lung injury and functions to suppress anti-inﬂammatory
epithelial mTORC1 responses. We administered intratracheal lipopolysaccharide to wild-type mice and
observed a signiﬁcant increase in lung Rtp801 mRNA. In lipopolysaccharide-treated Rtp801/ mice,
epithelial mTORC1 activation signiﬁcantly increased and was associated with an attenuation of lung
inﬂammation. We reversed the anti-inﬂammatory phenotype of Rtp801/ mice with the mTORC1 in-
hibitor, rapamycin, reassuring against mTORC1-independent effects of Rtp801. We conﬁrmed the
proinﬂammatory effects of Rtp801 by generating a transgenic Rtp801 overexpressing mouse, which
displayed augmented inﬂammatory responses to intratracheal endotoxin. These data suggest that
epithelial mTORC1 activity plays a protective role against lung injury, and its inhibition by Rtp801
exacerbates alveolar injury caused by endotoxin. (Am J Pathol 2014, 184: 2382e2389; http://
dx.doi.org/10.1016/j.ajpath.2014.06.002)Supported by NIH grants K08 HL105538 (E.P.S.), R01 ES016285
(R.M.T.), and T32 HL007171 (D.H.-S.).
Disclosures: The ptetSplice801 ﬂag plasmid was provided by Quark
Pharmaceuticals (Fremont, CA).In the past decade, increasing scientiﬁc attention has been
devoted to the role of the mechanistic (formerly mamma-
lian) target of rapamycin (mTOR) in the maintenance of
cellular homeostasis.1 mTOR signaling occurs via two well-
deﬁned, evolutionarily conserved complexes named
mTORC1 and mTORC2. mTORC1, the best characterized
of the mTOR complexes, primarily functions in the trans-
duction of cell growth signals. mTORC1 signaling is acti-
vated during states of nutrient (eg, amino acids, lipids, and
glucose) availability and growth factor stimulation. Acti-
vated mTORC1, in turn, activates downstream targets such
as ribosomal S6 kinase, promoting protein synthesis and cell
growth.2 Accordingly, nutrient deprivation and environ-
mental stress attenuate mTORC1 signaling, mediated by
several upstream pathways that converge on the mTORC1
inhibitory complex TSC-1 (hamartin)/TSC-2 (tuberin).stigative Pathology.
.Acute respiratory distress syndrome (ARDS) is a common
and morbid critical illness characterized by the diffuse and
rapid onset of neutrophilic pulmonary inﬂammation in
response to either a direct (eg, pneumonia) or an indirect (eg,
nonpulmonary sepsis) pulmonary insult.3 Several known
modiﬁers of mTOR signaling have been implicated in the
pathophysiological characteristics of ARDS, such as oxida-
tive stress and localized hypoxia (both of which inhibit
mTORC14,5), as well as local inﬂammatory cytokine
expression (associated with mTORC1 activation6). Interest-
ingly, published reports conﬂict regarding the impact of
Rtp801 Augments LPS Lung InﬂammationmTORC1 signaling in ARDS.7e10 Because these conﬂicting
studies were on the basis of the systemic use of the phar-
macological mTORC1 inhibitor rapamycin, their discrepant
results could reﬂect varied effects of mTORC1 across the
complex multicellular microenvironment of the injured
alveolus. Furthermore, few studies have addressed the
endogenous regulation of mTORC1 signaling during the
onset and progression of lung injury.
In mice, cigarette smoke inhalation increases pulmonary
expression of Rtp801 (alias Redd1 or Ddit4), an endogenous
activator of TSC-2, and, consequently, inhibitor of mTORC1.4
Within the lungs, Rtp801 is primarily localized to type II
alveolar epithelial cells.4 Rtp801-mediated inhibition of
epithelial mTORC1 activity during cigarette smoke inhalation
augments alveolar injury, contributing to emphysema forma-
tion. Concordantly, RTP801 expression is increased in lung
samples collected from human subjects with emphysema.4
These ﬁndings indicate that Rtp801/mTORC1 signaling
functions to sense environmental stressors, integrating
epithelial injury responses within the lungs.
Given that bacterial-originated lipopolysaccharide (LPS)
might be recognized as an environmental threat, we hypothe-
sized that Rtp801 expression would increase in a mouse LPS
model of ARDS, with the ensuing suppression of epithelial
mTORC1 consequently augmenting lung inﬂammation. We
investigated this hypothesis by using a model of direct (intra-
tracheal LPS) lung injury in wild-type (WT) mice and Rtp801-
knockout (Rtp801/) mice. These investigations were
complemented by the development of transgenic mice that
overexpressed Rtp801, to determine whether mTORC1 inhibi-
tion would lower the threshold for LPS-induced lung injury.
Neutrophilic inﬂammation was correlated to cell-speciﬁc mea-
sures of mTORC1 activity, demonstrating the complex cellular
heterogeneity of mTORC1 activity within the injured lung.
Materials and Methods
Reagents
LPS (Escherichia coli 055:B5), rapamycin, and dimethyl sulf-
oxide (DMSO) were purchased from Sigma (St. Louis, MO).
Animals
All mouse experiments were approved by the Institutional
Animal Care and Use Committee of the University of
Colorado (Aurora, CO). The care and handling of animals
were in accord with NIH guidelines for ethical animal
treatment. Animals were maintained in standard housing at
the University of Colorado Anschutz Medical Center with
ad libitum access to food and water. Animals of identical
age and housing (ie, littermates) were randomly assigned to
experimental or control groups.
We generated 8- to 12-week-old Rtp801/ male mice
(C57BL/6 x 129SvEv) and WT littermates, as previously
described.4 To generate Rtp801-overexpressing mice, ratThe American Journal of Pathology - ajp.amjpathol.orgDdit4 gene (encoding Rtp801) was ﬁrst cloned and sequenced.
The ptetSplice801 ﬂag plasmid provided by Quark Pharma-
ceuticals (Fremont, CA) was ampliﬁed in E. coli, and the
EcoRI-restricted product (780 Kb) was used as a template to
clone the Ddit4 gene. The ptetSplice801 ﬂag EcoRI fragment
was PCR ampliﬁed using the forward primer JBO-5 (50-
CGGATCCGCCACCATGGAGCAAAAGCTGATTTCTGA-
GGAGGATCTGCCTAGCCTCTGGGATCG-30), which
added a BamHI restriction site, a myc ﬂag, and a Kozak
sequence to the Rtp801 coding sequence. The reverse
primer JBO-2 (50-GAAGCTTCAACACTCTTCAATG-
AGCA-30) was used to amplify the Rtp801 coding sequence,
including a HindIII restriction site. The 731-bp PCR product
was puriﬁed and cloned using the TA-TOPO cloning system
(Invitrogen, Carlsbad, CA), following the conditions described
by the manufacturer. Colonies were screened via restriction
with EcoRI. Clones with inserts of the correct size were
sequenced with Ampli Taq DNA polymerase FS (Applied
Biosystems, Foster City, CA) with the dRhodamine terminator
cycle-sequencing ready-reaction kit (Applied Biosystems) at
the DNA sequencing and analysis core facility of the University
of Colorado Cancer Center and analyzed with the PC/GENE
software version 6.7 (IntelliGenetics, Mountain View, CA).
The selected TOPO myceRTP-801 plasmid was ampliﬁed in
E. coli and restricted with BamHI and HindIII. The released
fragments were cloned into the BamHI and HindIII of the
pTRE2 vector (Clontech Laboratories, Mountain View, CA),
following the conditions described by the manufacturer. Col-
onies were screened via restriction with BamHI and HindIII
enzymes. Clones with inserts of the correct size were sequenced
as described above. The pTRE2emyceRTP-801 plasmid was
ampliﬁed in E. coli, and the XhoI/SapI-restricted puriﬁed
product (2.4 Kb) was used for injection in an egg of the
C57BL6 mouse strain in the Transgenic Mouse Core of the
University of Cincinnati (Cincinnati, OH) to produce the Tg-
TREeRTP-801 mouse.
Mouse Model of Lung Injury
Brieﬂy, we anesthetized mice with i.p. ketamine and xylazine
and suspended them by their incisors in a prone position at a 45-
degree angle. We visualized the vocal cords using a small-
animal laryngoscope (Penn-Century, Wyndmoor, PA) and
instilled LPS (2 mg/kg in PBS; total volume, 50 mL) or 50 mL
PBS for control into the trachea using a MicroSprayer aerosol-
izer (Penn-Century). At 4 or 24 hours after tracheal instillation,
we re-anesthetized the mice with i.p. ketamine and xylazine.
Once anesthetized, mice were sacriﬁced via exsanguination and
bilateral thoracotomies. We performed bronchoalveolar lavage
(BAL) with three 1-mL aliquots of ice-cold PBS and/or har-
vested lungs for analysis, as previously described.4
Rtp801-TRE Experiments
Ten days before acute lung injury experiments, we induced
expression of the Rtp801 transgene by the intratracheal2383
Nadon et aladministration of 1  109 plaque-forming units (in 50 mL
PBS) of the tet-off tTA-adenovirus [or green ﬂuorescent
protein (GFP)eadenovirus as control] to Tg-TRE-RTP-801
mice anesthetized with ketamine/xylazine. After completion
of the experimental protocol (24 hours after LPS), expression
of the Rtp801 transgene was conﬁrmed via mRNA quanti-
tative real-time PCR (qPCR) and protein immunoﬂuores-
cence, as described below. Concurrent suppression of
mTORC1 signaling was conﬁrmed by immunoﬂuorescent
identiﬁcation of the downstream mTORC1 target phos-
phorylated ribosomal S6, as described below.
Rapamycin Reversal of Rtp801 Knockout Phenotype
As previously described,4 we treated WT mice and Rtp801-
knockout mice with either 1.8% DMSO in PBS (200 mL,
administered via i.p. injection) or rapamycin (1 mg/kg;
diluted in 200 mL 1.8% DMSO in PBS) daily for 7 days
before treatment with intratracheal LPS (2 mg/kg). Twenty-
four hours after LPS, we performed BAL and harvested
organs for analysis, as described above.
Assessment of Pulmonary Inﬂammation
We performed BAL differential counts, as previously
described.4 Brieﬂy, we determined the total BAL ﬂuid cell
count using a Bright-Line Hemacytometer (Hausser Scien-
tiﬁc, Horsham, PA). We calculated neutrophil differentials
using cytospins from aliquots of BAL ﬂuid after staining
using the Hema 3 manual staining protocol (Fisher Scien-
tiﬁc, Waltham, MA).
Assessment of Pulmonary Histological Characteristics
We performed histological analysis on parafﬁn-embedded,
formalin-ﬁxed sections (4 mm thick), as previously
described.4 An automated tissue stainer (Shandon Varistain
Gemini ES; Thermo Scientiﬁc, Waltham, MA) performed
hematoxylin and eosin staining. Slides were randomized and
coded. A pathologist (R.M.T.), masked to slide identity,
quantiﬁed lung injury using an American Thoracic Societye
endorsed scoring system.11 This score, ranging from 0 (no
injury) to 1 (severe injury), is on the basis of a weighted
average of neutrophils in the alveolar space, neutrophils in
the interstitial space, hyaline membranes, proteinaceous
airspace debris, and alveolar septal thickening.11 The mean
linear intercept was determined in saline-treated WT and
RTP801/ mice (Metamorph, Molecular Devices, Sunny-
vale, CA), as previously described.4 In addition, the alveolar
surface volume (S/V) ratio was determined stereologically
in the left lung. Images consisted of alveolated left lung,
excluding areas that contained large airways or vessels. The
lowest magniﬁcation that allowed proper resolution was
10. The grid consisted of 21 line segments for determi-
nation of alveolar septal intercepts (indicative of alveolar
surface). Lung volume was estimated by point count using a238442-point grid, and positive counts referred to points that fell
in lung tissue (septa, vessels, airways, and airspace). The












I represents the sum of alveolar septal intercepts
across line probe;
P
PL : sum of points falling within the
lung; and L/P: the ratio of line probe length/total point
probes.
The images were processed by Metamorph digital pro-
cessing, and a macro operation was developed that super-
imposed the sampling line/point grid to binary-processed
images; positive events were then counted per image and
summed to provide the total number of events per lung.
Immunoﬂuorescence
We performed immunoﬂuorescence, including colocaliza-
tion experiments, on parafﬁn-embedded, formalin-ﬁxed
sections (4 mm thick) of agarose inﬂated lungs, as previ-
ously described.12 Primary antibodies included rabbit
polyclonal antibody to phospho-S6 ribosomal proteine
Ser235/236 (1:300, number 2211; Cell Signaling, Danvers,
MA), goat polyclonal antibody to surfactant protein C (SPC;
1:100, sc-7705; Santa Cruz Biotechnology, Santa Cruz,
CA), goat polyclonal antibody to Redd-1 (ie, Rtp801; 1:100,
sc-46034; Santa Cruz Biotechnology), rat monoclonal
antibody to mouse Mac-3 (1:50, M3/84; BD Pharmingen,
San Jose, CA), and rat monoclonal antibody to mouse
Ly-6B.2 (1:100, MCA771G; Abd Serotec, Raleigh, NC).
Isotype antibodies served as negative controls: rabbit IgG
(1:200, I-1000; Vector Laboratories, Burlingame, CA), goat
IgG (1:200, I-5000; Vector Laboratories), and rat IgG
(1:200, I-4000; Vector Laboratories). We performed image
quantiﬁcation using Metamorph, as previously described.13
Protein and mRNA Expression
After completion of the experimental protocol (4 or 24 hours
after LPS), we harvested lungs for protein or mRNA analysis.
Western blot analyses were completed as previously
described.12 Primary antibodies included the following:
polyclonal rabbit antibody to phospho-S6 ribosomal proteine
Ser235/236 (1:20,000, number 2211; Cell Signaling), poly-
clonal rabbit antibody to S6 ribosomal protein (1:20,000,
number 2217; Cell Signaling), and polyclonal rabbit antibody
to b-actin (1:40,000, number 4967; Cell Signaling).
Total RNAwas extracted from lung homogenates by using
the RNeasy kit (Qiagen, Valencia, CA). RNA concentration
was determined by spectrophotometry. The expression of
Rtp801 in the transgenic samples after doxycycline induction
was assessed by RT-qPCR using the primers TgTRERTP
forward (50-CCATGGAGCAAAAGCTGATT-30) and
TgTRERTP reverse (50-ACTGTTGCTGCTGTCCAGG-30)ajp.amjpathol.org - The American Journal of Pathology
Rtp801 Augments LPS Lung Inﬂammationunder the following conditions: an aliquot of 1 mg of total
RNA (without DNase treatment) was reverse transcribed
with the iScript Reverse Transcription Supermix (Bio-Rad
Laboratories, Hercules, CA) in 20 mL of total volume, ac-
cording to the manufacturer’s instructions. Samples were
then stored at 20C.
Real-time PCR was performed using the 7300 Real Time
PCR System (Applied Biosystems) with SYBR Green PCR
Master Mix (Applied Biosystems), as follows: 2 mL of the
appropriate dilution of the cDNA sample plus 18 mL of a
premade mixture containing 0.5 mL 10 mmol/L TgTRERTP
forward primer, 0.5 mL 10 mmol/L TgTRERTP reverse
primer, 10 mL 2 SYBER Green PCR Master Mix (HS
SYBR Green qPCR kit), and 7.0 mL H2O. The cycling
parameters were as follows: stage 1, 50C for 2 minutes;Figure 1 Rtp801 suppresses LPS activation of epithelial mTORC1. A: Four h
signiﬁcantly increased in WT mice, as assessed by qPCR. Rtp801 expression is abse
housekeeping gene cyclophilin A. Pulmonary mTORC1 activity (assessed by the re
nonsigniﬁcantly 4 hours after 2 mg/kg intratracheal LPS, as assessed by Western b
the absence of Rtp801, LPS signiﬁcantly increases pulmonary mTORC1 activity, de
pulmonary mTORC1. Immunoﬂuorescent colocalization demonstrates that loss of R
cells (SPC positive, D) 4 hours after 2 mg/kg intratracheal LPS. No increase in p-S6
green, SPC (D), Ly-6B.2 (neutrophil marker, E), or Mac3 (macrophage marker, F); y
6B.2 (n Z 2). Scale bars: 10 mm (C); 50 mm (DeF).
The American Journal of Pathology - ajp.amjpathol.orgstage 2, 95C for 10 minutes; stage 3 (40 cycles), 95C for
15 seconds and 60C for 1 minute; and stage 4 (dissocia-
tion), 95C for 15 seconds, 60C for 30 seconds, and 95C
for 15 seconds.
Relative gene expression (in comparison to both exper-
imental controls and the housekeeping gene, cyclophilin A)
was determined by the comparative CT method (2
DDCT).
In studies demonstrating absence of Rtp801 in knock-
out mice, expression was determined only in compari-
son to cyclophilin A (2DCT). Primers for cyclophilin A
were m_rCycl74 forward (50-CGACTGTGGACAGCTCTA-
AT-30) and m_rCycl74 reverse (50-CCTGAGCTACA-
GAAGGAATG-30). qPCR was similarly performed for heme
oxygenase 1 [HO-1; forward (50-GGTCAGGTGTCCAGAG-
AAGG-30); reverse (50-CTTCCAGGGCCGTGTAGATA-30)]ours after 2 mg/kg intratracheal LPS, pulmonary expression of Rtp801 is
nt in Rtp801/ mice. Expression is quantiﬁed as 2DCT, normalized to the
lative phosphorylation of the mTORC1 target ribosomal S6, p-S6) increases
lot analysis of lung homogenates (B) and lung immunoﬂuorescence (C). In
monstrating that Rtp801 induction functions to suppress LPS activation of
tp801 augments mTORC1 signaling (p-S6) within alveolar type II epithelial
is noted within neutrophils (E) or macrophages (F). Red, p-S6; blue, DAPI;
ellow, colocalization. *P < 0.05. nZ 3 to 5 per group, except WT saline Ly-
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Nadon et alandwith a TaqMan predesigned assay for tumor necrosis factor-
a (TNF-a; number 4331182; Applied Biosystems).
Statistical Analysis
Data are expressed as either scatter plots (accompanied by
means) or bar graphs with SEM. We used a Student’s two-
tailed t-test when comparing two groups. Multiple com-
parisons were performed by one-way analysis of variance
with Bonferroni’s post hoc testing. Differences were sta-
tistically signiﬁcant if P  0.05. We performed all calcu-
lations using Prism version 5 (GraphPad, La Jolla, CA).
Results
LPS-Induced Lung Inﬂammation Is Exacerbated by
Rtp801 Suppression of mTORC1
Intratracheal administration of LPS was associated with a
rapid (4-hour) increase in pulmonary Rtp801 transcript
expression (Figure 1A). WT animals demonstrated a
nonsigniﬁcant trend toward increased pulmonary mTORC1
activity after LPS, as assessed by increased phosphorylation
of ribosomal S6, a downstream target of mTORC1/S6K2386(Figure 1, B and C). In the absence of Rtp801, LPS induced a
substantial and statistically signiﬁcant increase in mTORC1
activity (Figure 1, B and C), demonstrating that Rtp801
suppresses the pulmonary mTORC1 response to intratracheal
LPS injury.
The impact of Rtp801 on mTOR signaling was most
apparent within alveolar type II cells (Figure 1D), reﬂecting
our previous observations that pulmonary Rtp801 was pri-
marily localized to the alveolar epithelium.4 Consistent with
this epithelial speciﬁcity, mTORC1 activity in pulmonary
neutrophils (Figure 1E) and macrophages (Figure 1F) did
not increase after intratracheal LPS and was not inﬂuenced
by the absence of Rtp801.
Rtp801 Inﬂuences Pulmonary Inﬂammation via
Regulation of mTORC1 Signaling
We sought to determine whether alteration of epithelial
mTORC1 signaling (as measured 4 hours after intratracheal
LPS) (Figure 1) affected the later development of neutrophilic
pulmonary inﬂammation. In accordance with our previous
ﬁndings,4 there were no baseline differences in lung
morphometry ﬁndings betweenWT and Rtp801/mice, with
similar mean linear intercepts (28.1  1.5 versus 27.0  0.55Figure 2 Rtp801 suppression of mTORC1 aug-
ments lung inﬂammation after LPS. Twenty-four
hours after 2 mg/kg intratracheal LPS, signiﬁcant
pulmonary inﬂammation is apparent in lung his-
tological features (hematoxylin and eosin, as
quantiﬁed by a lung injury score ranging in
severity from 0 to 1) (A) and BAL (B). Inﬂamma-
tion is signiﬁcantly attenuated in Rtp801/ mice
(A and B), demonstrating that epithelial mTORC1
activity functions to suppress pulmonary inﬂam-
mation after intratracheal injury. C: The anti-
inﬂammatory phenotype of Rtp801/ mice is
lost after pretreatment with the mTORC1 inhibitor,
rapamycin (Rapa; 1 mg/kg administered i.p. daily
for 7 days before LPS), conﬁrming that pulmonary
mTORC1 activity opposes neutrophilic inﬂamma-
tion after intratracheal LPS. DMSO served as
diluent control. Lung homogenate qPCR for HO-1
(D) and TNF-a (E) in WT or Rtp801/ mice 24
hours after intratracheal saline or LPS. Expression
is quantiﬁed as 2DDCT, normalized to both the
housekeeping gene cyclophilin A and intratracheal
saline controls. *P < 0.05 (BeE). nZ 3 to 10 per
group (A and B); nZ 3 to 9 per group (C); nZ 3
to 4 per group (D and E). Scale barZ 100 mm (A).
ajp.amjpathol.org - The American Journal of Pathology
Rtp801 Augments LPS Lung Inﬂammationmm) and S/V ratios (0.01 0.003 mm1 versus 0.01 0.0001
mm1), respectively (n Z 4 to 6 per group). Pulmonary
inﬂammation 24 hours after intratracheal LPS was attenuated
by loss of Rtp801, as demonstrated by a dramatic attenuation
of neutrophilic lung inﬁltration (Figure 2A). This protective
effect was conﬁrmed by an attenuation of alveolar neutrophilia
in BAL ﬂuid (Figure 2B). The anti-inﬂammatory phenotype of
Rtp801/ mice was reversed by pretreatment with the
mTORC1 inhibitor, rapamycin (Figure 2C), demonstrating
that the effect of Rtp801 loss was directly consequent to
augmented mTORC1 signaling. Interestingly, rapamycin
pretreatment had a trend (P Z 0.18) toward a paradoxically
anti-inﬂammatory effect in LPS-treated WT mice, consistent
with our previous ﬁndings.4
We sought to determine the mechanism underlying the
anti-inﬂammatory phenotype of Rtp801/mice. There were
no differences in TUNEL staining (data not shown) between
WT and Rtp801/ mice 24 hours after intratracheal LPS,
suggesting that loss of Rtp801 does not affect endotoxin-
induced alveolar cell apoptosis. However, Rtp801/ mice
demonstrated suppression of HO-1 (Figure 2D), a marker of
(and potentially contributor to) oxidative stress.14,15 Simi-
larly, Rtp801/ mice demonstrated suppression of TNF-a
expression (Figure 2E) 24 hours after intratracheal LPS,
suggesting that Rtp801-regulated mTORC1 activity in-
ﬂuences the proinﬂammatory alveolar microenvironment.
Given the anti-inﬂammatory impact of loss of Rtp801, we
anticipated that Rtp801 overexpression would augment LPS-Figure 3 Intratracheal (IT) overexpression of Rtp801 suppresses pulmo
A: Intratracheal transfection of Tg-TREeRTP-801 mice with the tet-off TTA ade
Tg-TREeRTP-801 mice transfected with a GFP-expressing adenoviral control. Expr
cyclophilin A and GFP-AAVetreated controls. B: Conﬁrmation of Rtp801 (red) over
801 mice using immunoﬂuorescence. C: Transgenic Rtp801 overexpression app
attenuation of S6 phosphorylation (p-S6) 4 hours after 2 mg/kg intratracheal LPS
SPC. DAPIZ nuclear stain. D: Rtp801 overexpression augments pulmonary neutrop
LPS. E: These ﬁndings are supported by a trend toward increased lung injury in LPS-
group. Scale bars: 50 mm (B and C); 100 mm (E).
The American Journal of Pathology - ajp.amjpathol.orginduced pulmonary inﬂammation. We inhibited pulmonary
epithelial mTORC1 signaling by generating a transgenic
mouse overexpressing the rat Ddit4 gene under the control
of a tetracycline reverse transactivator. After intratracheal
installation of an adenovirus containing the tet-off tTA-
adenovirus (leading to continuous transgene expression in
the absence of tetracycline), Rtp801 transgene expression
was apparent via qPCR of lung homogenates (Figure 3A)
and via immunoﬂuorescence of lung tissue sections
(Figure 3B). The transgene was biologically active, as
demonstrated by a decrease in epithelial mTORC1 signaling
(Figure 3C) 4 hours after LPS. This loss of mTORC1 ac-
tivity augmented lung inﬂammation 24 hours after LPS, as
demonstrated by increased BAL neutrophil counts
(Figure 3D) and a trend toward worsened histological lung
injury scores (Figure 3E). The phenotypes of Rtp801/ and
overexpressing Tg-TREeRTP-801 mice, therefore,
consistently demonstrate an anti-inﬂammatory effect of
mTORC1 signaling, with action occurring at least in part
through alveolar epithelial cells.Discussion
Alterations of mTOR signaling participate in disease pro-
cesses as diverse as obesity and diabetes, cancer growth, and
immune dysregulation.1 However, research into the teleo-
logical role of pulmonary mTORC1 as a hub regulatingnary mTORC1 activity and augments LPS-induced lung inﬂammation.
novirus increases pulmonary Rtp801 expression by 91% in comparison to
ession is quantiﬁed as 2DDCT, normalized to both the housekeeping gene
expression within alveoli of TTA-AAVepretreated, LPS-treated Tg-TREeRTP-
ropriately functions to suppress mTORC1, as demonstrated by a dramatic
. High-magniﬁcation inset demonstrates p-S6 colocalization (arrows) with
hilic inﬂammation, as apparent in BAL 24 hours after 2 mg/kg intratracheal
treated, Rtp801-overexpressing mice. *P < 0.05, yPZ 0.05. nZ 3 to 4 per
2387
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lung has lagged behind other ﬁelds of investigation. We
have recently identiﬁed a key role of epithelial Rtp801/
mTOR signaling in the pathogenesis of cigarette smokee
induced pulmonary injury.4 We now extend these observa-
tions, identifying that induction of Rtp801 importantly
contributes to LPS-induced lung inﬂammation via the sup-
pression of alveolar epithelial mTORC1 signaling.
On the basis of our ﬁndings, we propose that alveolar
epithelial mTORC1 activity is induced during endotoxin-
induced lung injury but is concomitantly attenuated by the
induction of endogenous Rtp801. In the absence of Rtp801
suppression, alveolar mTORC1 signaling is signiﬁcant and
attenuates the neutrophil inﬂux characteristic of ARDS.
The proinﬂammatory impact of airway/alveolar Rtp801
overexpression corroborates these ﬁndings, further under-
lining that epithelial mTORC1 signaling attenuates
inﬂammation after intratracheal LPS. In contrast, mTORC1
activity within other alveolar cell types (including inﬂam-
matory cells recruited to the injured lung7,10) may have
discrepant effects, possibly leading to the variable obser-
vations made by us (Figure 2C and previous ﬁndings4) and
others7e10 using systemic, pharmacological inhibition of
mTORC1 (ie, rapamycin) across the injured alveolar
microenvironment.
As a master sensor of environmental stress, mTORC1 is
ideally positioned to inﬂuence the onset and progression of
ARDS, an inﬂammatory lung disease triggered by direct or
indirect environmental stressors. Indeed, mTORC1 regu-
lates numerous processes that directly and indirectly affect
lung injury, including apoptosis, oxidative stress, and in-
ﬂammatory signaling.4 Although we were unable to detect a
difference in apoptosis between injured WT and Rtp801/
mice, our data demonstrate the broad impact of Rtp801-
regulated mTORC1 signaling on oxidative stress
(Figure 2D) and inﬂammation (Figure 2E). In accordance
with this proximal role in controlling diverse cellular pro-
cesses, mTORC1 is highly regulated by a variety of up-
stream (largely inhibitory) endogenous signaling pathways.1
Interestingly, these inhibitory pathways impart dramatically
different effects on the lung after an inﬂammatory stimulus.
Our observed anti-inﬂammatory effect of mTORC1 is
corroborated by several recent studies. Katholnig et al16
demonstrated that mTORC1 activation by p38a-MK2 pro-
motes production of the anti-inﬂammatory cytokine IL-10.
Similarly, Ivanov and Roy17 identiﬁed that mTORC1
serves as a translational rheostat, favoring the translation of
mRNA encoding anti-inﬂammatory cytokines (eg, IL-10).
Interestingly, studies of other upstream regulators of
mTORC1 activity have not clearly demonstrated an anti-
inﬂammatory effect of mTORC1. AMP-activated protein ki-
nase inhibition of mTORC1 attenuated LPS-induced18,19 and
bleomycin-induced20 lung injury, whereas it conversely
exacerbated wood smokeeinduced21 and ozone-induced22
lung injury. DEPTOR, an endothelial inhibitor of mTORC1
(as well as extracellular signaleregulated kinase 1/2 and2388STAT1 signaling), has been associated with suppression of
chemokine and adhesion molecule expression, suggesting
anti-inﬂammatory function.23
The mechanisms underlying the variable effects of different
pathways of mTORC1 inhibition are unclear. Differential
tissue expression of various mTORC1 inhibitory pathways
could impart varied effects during pulmonary inﬂammation,
indicative of cellular heterogeneity of mTORC1 function
within the lung. Our ﬁndings, which indicate an epithelial
localization of Rtp801/mTORC1 signaling, suggest that
alveolar epithelial mTORC1 suppresses pulmonary inﬂam-
matory responses to intratracheal LPS. Alternatively, the
differing effects of alternative mTORC1 inhibitory pathways
could indicate that these pathways impart additional non-
speciﬁc, mTORC1-independent effects. The reversal of the
protective phenotype of Rtp801/ mice by the mTORC1
inhibitor, rapamycin (Figure 2C), reassures us that the
observed proinﬂammatory effects of Rtp801 in our model are
mTORC1 dependent.
mTORC1 signaling signiﬁcantly affects key processes
underlying the onset of lung inﬂammation. The control of
this signaling is highly complex, potentially reﬂecting
differential tissue expression of mTORC1 regulatory ma-
chinery, such as Rtp801. Future studies with conditional,
tissue-speciﬁc manipulation of mTORC1 function are
needed to further investigate the alveolar heterogeneity of
mTORC1 signaling during lung injury.Acknowledgments
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